Clomid

Clomiphene Citrate is a selective estrogen receptor modulator (SERM) first approved by the FDA in 1967 under the brand name Clomid for the treatment of female anovulatory infertility. It is a racemic mixture of two geometric isomers — zuclomiphene (cis) and enclomiphene (trans) — each with distinct pharmacological profiles. Enclomiphene acts primarily as an estrogen receptor antagonist at the hypothalamus and pituitary, while zuclomiphene exhibits mixed agonist/antagonist activity with a significantly longer half-life. This dual nature defines both the compound's therapeutic utility and its side-effect profile.

Clomiphene's mechanism in post-cycle therapy (PCT) centers on its antagonism of estrogen receptors in the hypothalamus and anterior pituitary. By blocking estrogen's negative feedback signal at these sites, Clomiphene triggers a compensatory increase in gonadotropin-releasing hormone (GnRH) pulsatility, which in turn stimulates the pituitary to release luteinizing hormone (LH) and follicle-stimulating hormone (FSH). Elevated LH directly signals Leydig cells in the testes to resume endogenous testosterone production — the core objective of any PCT protocol. Clinical studies in hypogonadal males demonstrate significant elevations in serum testosterone (often doubling or tripling baseline) within 2–4 weeks of initiation.

Clomid is a foundational PCT compound. Following the suppression of the hypothalamic-pituitary-testicular axis (HPTA) that occurs with exogenous androgen administration, Clomiphene accelerates the recovery of endogenous hormonal function. Without PCT intervention, natural testosterone recovery can take months and may remain incomplete, leading to loss of gains, fat accumulation, mood disturbance, and sexual dysfunction. Clomid addresses this by pharmacologically restarting the signaling cascade.

Clomid is appropriate for researchers at all experience levels as a PCT compound. It is often paired with Nolvadex (Tamoxifen) for a synergistic two-SERM PCT protocol — the combination provides both hypothalamic-level stimulation (Clomid's strength) and robust receptor-level anti-estrogenic protection (Nolvadex's strength). Clomid may also be used as a standalone PCT for milder cycles or SARM-only protocols.

Clomiphene Citrate has a half-life of approximately 5–7 days due to the slow clearance of the zuclomiphene isomer, though peak serum levels are achieved within 4–6 hours of oral administration. Standard PCT dosing begins 2–3 weeks after the last injection of a long-ester injectable (or 3–5 days after a short-ester/oral-only cycle). A common protocol is 50 mg daily for 2 weeks followed by 25 mg daily for 2 weeks. Clomid is not hepatotoxic. The most commonly reported side effects are visual disturbances (blurred vision, floaters — typically reversible and dose-dependent), emotional lability, and mood swings — effects attributed primarily to the zuclomiphene isomer. If visual disturbances occur, discontinuation is recommended.